Thromb Haemost 2001; 86(05): 1141-1143
DOI: 10.1055/s-0037-1616041
In Focus
Schattauer GmbH

A Prospective Evaluation of the Interleukin-1 Receptor Antagonist Intron 2 Gene Polymorphism and the Risk of Myocardial Infarction

Robert Y. L. Zee
1   Center for Cardiovascular Disease Prevention, the Leducq Center for Molecular and Genetic Epidemiology of Cardiovascular Disorders, the Division of Preventive Medicine, Boston, MA, USA
,
Karsten Lunze
2   Division of Endocrine-Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
,
Klaus Lindpaintner
2   Division of Endocrine-Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
,
Paul M. Ridker
1   Center for Cardiovascular Disease Prevention, the Leducq Center for Molecular and Genetic Epidemiology of Cardiovascular Disorders, the Division of Preventive Medicine, Boston, MA, USA
› Author Affiliations
Supported by grants HL58755 and HL63293 from the National Heart, Lung, and Blood Institute, an Established Investigator Award from the American Heart Association, and by a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation (P.M.R.).
Further Information

Publication History

Received 30 March 2001

Accepted after revision 05 April 2001

Publication Date:
13 December 2017 (online)

Summary

While an interleukin-1 receptor antagonist gene polymorphism (IL1RN-VNTR) has recently been hypothesized to be a risk factor for coronary artery disease, no prospective data relating this polymorphism to subsequent risk of coronary events are available. We therefore investigated the association between IL1RN-VNTR genotype and the incidence of myocardial infarction (MI) in a large, prospective cohort of initially healthy men. The IL1RN-VNTR was evaluated among 385 MI case subjects and an equal number of age- and smoking-matched control subjects during a 12-year follow-up. Overall, the allele and g enotype distributions were similar among cases and controls, both in the total cohort and in all subgroups evaluated. All observed genotype frequencies were in Hardy-Weinberg equilibrium. Furthermore, the relative risk in a comparison of homozygous mutant to homozygous wild-type was 0.89 (95%CI = 0.5-1.6; P = 0.9). In this large, prospective study, the IL1RN-VNTR gene polymorphism is not associated with risks of future MI. These data also highlight the importance of hypothesis testing studies in genetic epidemiology, particularly for hypotheses generated from small samples or post hoc subgroup analyses.

 
  • References

  • 1 Mattila KJ, Valtonen VV, Nieminen MS, Asikainen S. Role of infection as a riskl factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 1998; 26: 719-34.
  • 2 Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115-26.
  • 3 Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
  • 4 Mansfield JC, Holden H, Tarlow JK, di Giovine FS, McDowell TL, Wilson AG, Holdsworth CD, Duff GW. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine IL-1ra. Gastroenterology 1994; 106: 637-42.
  • 5 Cork MJ, Tarlow JK, Clay FE, Crane A, Blakemore AIF, McDonagh AJ, Messenger AG, Duff GW. An allele of interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata. J Invest Dermatol 1995; 104: 15S-16S.
  • 6 Blakemore AIF, Cox A, Gonzalez AM, Maskill JK, Hughes ME, Wilson RM, Ward JD, Duff GW. Interleukin-1 receptor antagonist allele (IL-1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 1996; 97: 369-74.
  • 7 Kornman KS, Crane A, Wang HY, di Giovine FS, Newman MG, Pirk FW, Wilson TG, Duff GW. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997; 24: 72-7.
  • 8 Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, Crossman DC. Interleukin-1 Receptor Antagonist Gene Polymorphism and Coronary Artery Disease. Circulation 1999; 99: 861-6.
  • 9 Ridker PM, Stampfer MJ. Assessment of genetic markers for coronary thrombosis: promise and precaution. Lancet 1999; 353: 687-8.
  • 10 Steering committee of the physicians’ health study research group.. Final report of the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989; 312: 129-35.
  • 11 Tarlow JK, Blakemore AIF, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-4.
  • 12 Bogardus Jr ST, Concato J, Feinstein AR. Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA 1999; 281: 1919-26.
  • 13 Iacoviello L, Donati MB, Gattone M. Possible different involvement of interleukin-1 receptor antagonist gene polymorphism in coronary single vessel disease and myocardial infarction. Circulation 2000; 101: e193.
  • 14 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
  • 15 Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
  • 16 Rubattu S, Ridker P, Stampfer MJ, Volpe M, Hennekens CH, Lindpaintner K. The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation 1999; 100: 1722-6.